Reyataz (Atazanavir)
| Brand Name: |
Reyataz |
| Generic Name: |
Atazanavir, ATV |
| Adult Single Dose: |
Treatment-naive patients: 300 mg with Norvir 100 mg once daily OR 400 mg once daily; when coadministered with Viread, the dose is 300 mg with Norvir 100 mg
Treatment-experienced patients: 300 mg with Norvir 100 mg once daily |
| Food & Liquid Restrictions: |
Take with food |
| Drug Class: |
PI |
|
|
|
The Basics
- Patient Information About Reyataz (Atazanavir) (PDF) (January 2013)
From Bristol-Myers Squibb Company
- An Overview of Reyataz (Atazanavir) (September 13, 2012)
From AIDSinfo
- Atazanavir (Reyataz) (March 28, 2012)
To read PDF, click here.
From AIDS InfoNet
- Reyataz (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- FAQs About Reyataz (Atazanavir) (January 25, 2012)
From The Body's "Ask the Experts" Forums
- Reyataz (Atazanavir) (September 28, 2008)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Reyataz (Atazanavir) Package Insert Revisions (January 16, 2008)
From U.S. Food and Drug Administration
- Atazanavir (Reyataz) (August 15, 2006)
From AIDS Treatment Data Network
- Labeling Changes for Atazanavir (Reyataz) (January 26, 2006)
To read PDF, click here.
From U.S. Food and Drug Administration
- HIV JournalView: Putting Atazanavir + Ritonavir on the Map (July/August 2005)
A study finds the combo is comparable to lopinavir/ritonavir in patients with some baseline protease inhibitor resistance.
From TheBodyPRO.com
VIEW ALL ARTICLES
News & Research
- Recent Changes to the Reyataz (Atazanavir Sulfate) Capsule Labeling (February 8, 2013)
From U.S. Food and Drug Administration
On TheBodyPRO.com
- New Public-Private Partnership Will Allow Brazil to Produce Patented Antiretroviral for National Treatment Program (December 7, 2012)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
 The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors (November 18, 2012)
From Journal Watch
On TheBodyPRO.com
- Reyataz and Kidney Stones (November/December 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
 HIV JournalView: September 2012 (October 15, 2012)
David Alain Wohl, M.D., explores recently published findings regarding access to HIV care in the U.S., the impact of pain on clinic no-shows, links between atazanavir and gall/kidney stones, anal sex and HIV among women, and the limits of echocardiography.
In HIV JournalView, from TheBodyPRO.com
- Maraviroc Plus Atazanavir/Ritonavir in a Nuke-Sparing Regimen in Treatment-Naive Patients (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- First Report: Atazanavir-Related Gallstones (Cholelithiasis) (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- AIDS 2012: Other Treatment Studies (August 1, 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Outcomes From Switches to Atazanavir/r in London (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
 SPARTAN: Two-Drug, NRTI-Sparing Strategies Continue to Disappoint (June 8, 2012)
From Journal Watch
On TheBodyPRO.com
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
